Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals, Inc. (symbol: PCSA) is a clinical-stage biopharmaceutical company, founded in October 2017 and headquartered in Hanover, Maryland. The company's mission is to develop products that can significantly improve the survival and quality of life for patients with high unmet medical needs, particularly in the field of oncology.
Processa Pharmaceuticals specializes in the development of Next Generation Chemotherapy (NGC) oncology drug products using a unique 'regulatory science' approach. The company's primary focus is to advance its pipeline of proprietary small molecule oncology drugs. These NGC products are new chemical entities designed to alter the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites, while preserving the original mechanisms of action that kill cancer cells.
The company's current pipeline includes three promising NGC treatments:
- NGC-Capecitabine (NGC-Cap): This therapy involves Capecitabine administered with PCS6422, aiming to enhance efficacy and reduce side effects.
- PCS3117 (NGC-Gemcitabine or NGC-Gem): A novel formulation intended to improve the therapeutic profile of Gemcitabine.
- PCS11T (NGC-Irinotecan or NGC-Iri): Another innovative treatment designed to optimize the benefits of Irinotecan.
Processa Pharmaceuticals is committed to leveraging its expertise in regulatory science to bring these next-generation treatments to market. The company's strategic partnerships and ongoing clinical trials play a crucial role in advancing its mission and providing hope to patients battling cancer. For the latest updates and more information, investors can contact Patrick Lin at plin@processapharma.com.
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced a public offering of 1,555,555 shares of common stock and common warrants, with a combined public offering price of $4.50 per share. The gross proceeds from the offering are expected to be $7.0 million. The common warrants will have an exercise price of $4.50 per share and a term of five years after their original issuance date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.04%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) successfully completed the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap), a cancer treatment metabolite. NGC-Cap provides 2-10 times greater exposure to its 5-FU metabolite than capecitabine administration, with better tolerance and positive preliminary efficacy results. The Phase 2 trial in advanced or metastatic breast cancer is based on the Phase 1b data, with NGC-Cap showing potential for improved efficacy and safety over capecitabine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
148.78%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. announces plans to expand the development of NGC-Cap into the treatment of advanced or metastatic breast cancer. The FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design, making the development a more efficient and straightforward path to approval. The expansion into breast cancer represents a larger market than colorectal cancer, with the potential to differentiate NGC-Cap from existing treatments for breast cancer. Processa plans to initiate the Phase 2 study in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.84%
Tags
Rhea-AI Summary
Processa Pharmaceuticals, Inc. announces a reverse stock split to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of outstanding common stock shares from approximately 24.6 million shares to approximately 1.2 million shares, with a split ratio of 1-for-20. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol 'PCSA' with the new CUSIP number 74275C304.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.37%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces CEO George Ng's corporate overview presentation at the Biotech Showcase 2024, focusing on developing next-gen chemotherapeutic drugs for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) provides interim analysis from its Phase 1b study of Next Generation Capecitabine (NGC-Cap), showing improved safety and efficacy over capecitabine. Patients received lower doses of NGC-Cap resulting in 5-FU exposure up to 10 times greater than capecitabine, with similar side effect profiles. FDA confirms NGC-Cap as a new chemical entity, suggesting higher efficacy and better safety profile. Fireside Chat on December 20, 2023, to discuss the data and corporate strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.36%
Tags
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces positive outcomes from a meeting with the FDA regarding the next Phase 2 study for Next Generation Capecitabine ('NGC-Cap') for cancer patients. The FDA provided helpful guidance on the study design and dosage regimen, based on positive interim results from the ongoing Phase 1b study. Processa anticipates beginning enrollment for the Phase 2 study in mid-2024, aiming to provide a better safety/efficacy profile for patients who cannot tolerate existing Capecitabine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.4%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces Dr. David Young, President of Research and Development, will present at the MedInvest Oncology Investor Conference. Processa CEO George Ng will be available for one-on-one meetings with investors at the conference venue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.53%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for cancer patients. CEO George Ng recently issued a letter to shareholders, emphasizing the company's pivot to focus on oncology drug product development and the potential for safer and more effective chemotherapy treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18%
Tags
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces the unexpected passing of Director Virgil Thompson at 83. Mr. Thompson served on the Board of Directors since 2017 and was previously on the Board of Directors of Promet Therapeutics, LLC. The company expresses great sadness and gratitude for his leadership and wisdom.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.77%
Tags
FAQ
What is the current stock price of Processa Pharmaceuticals (PCSA)?
The current stock price of Processa Pharmaceuticals (PCSA) is $0.53 as of February 21, 2025.
What is the market cap of Processa Pharmaceuticals (PCSA)?
The market cap of Processa Pharmaceuticals (PCSA) is approximately 2.6M.
What is Processa Pharmaceuticals, Inc.?
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oncology drug products.
When was Processa Pharmaceuticals founded?
Processa Pharmaceuticals was founded in October 2017.
Where is Processa Pharmaceuticals headquartered?
The company is headquartered in Hanover, Maryland.
What is the mission of Processa Pharmaceuticals?
The mission is to develop products that improve the survival and quality of life for patients with high unmet medical needs.
What does NGC stand for?
NGC stands for Next Generation Chemotherapy.
What are the main products in Processa Pharmaceuticals' pipeline?
The main products include NGC-Capecitabine (NGC-Cap), PCS3117 (NGC-Gemcitabine), and PCS11T (NGC-Irinotecan).
What is the unique approach of Processa Pharmaceuticals?
The company uses a 'regulatory science' approach to develop new chemical entities that enhance the properties of FDA-approved cancer drugs.
How can investors get more information about Processa Pharmaceuticals?
Investors can contact Patrick Lin at plin@processapharma.com for more information.
What recent achievements has Processa Pharmaceuticals made?
Recent achievements include advancements in their NGC treatments and ongoing clinical trials.
Does Processa Pharmaceuticals have any partnerships?
Yes, the company engages in strategic partnerships to advance its mission and bring new treatments to market.
Processa Pharmaceuticals Inc